药石科技2024年三季报点评：盈利能力短期承压，订单延续向好趋势

Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Views - Short-term profitability is under pressure, but there is a positive trend in order growth, indicating long-term growth potential [2][3]. Financial Summary - Revenue for 2022 was 1,595 million, projected to be 1,725 million in 2023, with a decline to 1,570 million in 2024, followed by increases to 1,783 million in 2025 and 2,067 million in 2026 [1]. - Net profit attributable to the parent company was 314 million in 2022, expected to decrease to 197 million in 2023 and further to 186 million in 2024, before recovering to 221 million in 2025 and 271 million in 2026 [1]. - Earnings per share (EPS) is projected to be 0.99 in 2023, 0.93 in 2024, 1.11 in 2025, and 1.36 in 2026 [1]. - The return on equity (ROE) is expected to decline from 11.8% in 2022 to 7.0% in 2023, with a gradual recovery to 8.2% by 2026 [1]. Order and Market Trends - The company has seen a steady increase in order amounts, with a more than 20% year-on-year growth in orders as of the first half of 2024 [3]. - Active customer count reached 726, up 8.77% year-on-year, with 137 new customers added, marking a 34.31% increase [3]. - Revenue from large multinational corporations (MNCs) grew by 45.84%, accounting for 29% of total revenue [3]. Valuation and Price Target - The target price has been raised to 43.29 from the previous 31.25, based on a price-to-earnings (PE) ratio of 39 times for 2025 [5][10].